» Articles » PMID: 37020562

Time Series Clustering of T Cell Subsets Dissects Heterogeneity in Immune Reconstitution and Clinical Outcomes Among MUD-HCT Patients Receiving ATG or PTCy

Abstract

Introduction: Anti-T-lymphocyte globulin (ATG) or post-transplant cyclophosphamide (PTCy) prevent graft-versus-host disease (GVHD) after hematopoietic cell transplantation (HCT), yet individual patients benefit differentially.

Methods: Given the sparse comparative data on the impact of cellular immune reconstitution in this setting, we studied flow cytometry and clinical outcomes in 339 recipients of 10/10 matched-unrelated donor (MUD) HCT using either ATG (n=304) or PTCy (n=35) for T cell manipulation along with a haploidentical PTCy control cohort (n=45). Longitudinal cellular immune reconstitution data were analyzed conventionally and with a data science approach using clustering with dynamic time warping to determine the similarity between time-series of T cell subsets.

Results: Consistent with published studies, no significant differences in clinical outcomes were observed at the cohort level between MUD-ATG and MUD-PTCy. However, cellular reconstitution revealed preferences for distinct T cell subpopulations associating with GVHD protection in each setting. Starting early after HCT, MUD-PTCy patients had higher regulatory T cell levels after HCT (p <0.0001), while MUD-ATG patients presented with higher levels of γδ T- or NKT cells (both p <0.0001). Time-series clustering further dissected the patient population's heterogeneity revealing distinct immune reconstitution clusters. Importantly, it identified phenotypes that reproducibly associated with impaired clinical outcomes within the same T cell manipulation platform. Exemplarily, patients with lower activated- and αβ T cell counts had significantly higher NRM (p=0.032) and relapse rates (p =0.01).

Discussion: The improved understanding of the heterogeneity of cellular reconstitution in MUD patients with T cell manipulation both at the cohort and individual level may support clinicians in managing HCT complications.

Citing Articles

Lower incidence of acute graft-versus-host disease with post-transplantation cyclophosphamide compared to anti-thymocyte globulin in higher-risk myelodysplastic syndrome.

Choi E, Han J, Park H, Park H, Choi Y, Lee J Bone Marrow Transplant. 2024; 59(9):1329-1331.

PMID: 38977776 DOI: 10.1038/s41409-024-02364-6.


Graft-versus-tumor effect of post-transplant cyclophosphamide-based allogeneic hematopoietic cell transplantation.

Nakamae H Front Immunol. 2024; 15:1403936.

PMID: 38903503 PMC: 11187280. DOI: 10.3389/fimmu.2024.1403936.


Early T-cell reconstitution predicts risk of EBV reactivation after allogeneic hematopoietic stem cell transplantation.

Huang J, Pan Z, Wang L, Zhang Z, Huang J, Jiang C Clin Exp Med. 2024; 24(1):22.

PMID: 38280072 PMC: 10821970. DOI: 10.1007/s10238-023-01270-3.

References
1.
Minculescu L, Marquart H, Ryder L, Andersen N, Schjoedt I, Friis L . Improved Overall Survival, Relapse-Free-Survival, and Less Graft-vs.-Host-Disease in Patients With High Immune Reconstitution of TCR Gamma Delta Cells 2 Months After Allogeneic Stem Cell Transplantation. Front Immunol. 2019; 10:1997. PMC: 6714591. DOI: 10.3389/fimmu.2019.01997. View

2.
Moiseev I, Pirogova O, Alyanski A, Babenko E, Gindina T, Darskaya E . Graft-versus-Host Disease Prophylaxis in Unrelated Peripheral Blood Stem Cell Transplantation with Post-Transplantation Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil. Biol Blood Marrow Transplant. 2016; 22(6):1037-1042. DOI: 10.1016/j.bbmt.2016.03.004. View

3.
Ferrara J, Levine J, Reddy P, Holler E . Graft-versus-host disease. Lancet. 2009; 373(9674):1550-61. PMC: 2735047. DOI: 10.1016/S0140-6736(09)60237-3. View

4.
Finke J, Bethge W, Schmoor C, Ottinger H, Stelljes M, Zander A . Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial. Lancet Oncol. 2009; 10(9):855-64. DOI: 10.1016/S1470-2045(09)70225-6. View

5.
Sanz J, Galimard J, Labopin M, Afanasyev B, Angelucci E, Ciceri F . Post-transplant cyclophosphamide after matched sibling, unrelated and haploidentical donor transplants in patients with acute myeloid leukemia: a comparative study of the ALWP EBMT. J Hematol Oncol. 2020; 13(1):46. PMC: 7201995. DOI: 10.1186/s13045-020-00882-6. View